-
Jilin Province Solicits Opinions on the Implementation Rules for the Management of Traditional Chinese Medicine Formula Granules
Time of Update: 2021-09-12
Article 12 If the Chinese medicine formula granules produced by other province's Chinese medicine formula granule production enterprises enter the medical institutions of Jilin Province for use, they shall be reported to the Provincial Drug Administration for the record, and the production enterprises and their varieties that have not been recorded shall not be sold and used in Jilin Province .
-
Overview of the procurement completion progress and usage proportion of 157 nationally sourced varieties
Time of Update: 2021-09-12
2. The second batch of national procurement The second batch of national procurement of Jiangxi selected drugs will enter the second procurement cycle from April 11, 2021, from April 11, 2021 to July 31, 2021, procurement The situation is as follows: Purchase quantity and amount .
-
Guangxi included 531 traditional Chinese medicine and ethnic medicine decoction pieces into the payment scope of medical insurance and work-related injury insurance funds
Time of Update: 2021-09-12
The bureau, together with the Human Resources and Social Security Department of Guangxi Zhuang Autonomous Region, issued relevant notices to include 531 traditional Chinese medicine and ethnic medicine decoction pieces that meet the conditions and have Guangxi local standards into the Guangxi basic medical insurance (including Maternity insurance) and the scope of payment from the work-related injury insurance fund .
-
The State Food and Drug Administration Revises the Instructions for Creatine Phosphate Sodium for Injection
Time of Update: 2021-09-12
Medical Network September 3 News State Food and Drug Administration announcement on the revision of muscle sodium phosphate injection instructions (2021 No.
105) according to Drug assessment of adverse reactions, to further protect public safety, the State Drug Administration decided The contents of the instructions for creatine phosphate sodium for injection have been revised and improved uniformly .
-
Fosun holds 5 top explosives, 72 innovative drugs and 18 biosimilar drugs
Time of Update: 2021-09-12
As an established pharmaceutical company, Fosun Pharma's generic drugs are also facing the impact of centralized procurement, and innovative products have become a strong "blood transfusion" support .
In the first half of the year, the sales revenue of Fosun Pharma's anti-tumor and immunomodulation core products increased by 256.
-
Cinda's 21 Class 1 New Drugs Expose, 3 New Drugs Attack Over 26 Billion Market
Time of Update: 2021-09-12
In addition, the listing application of Sintilimab injection for second-line squamous non-small cell lung cancer is under review and is expected to be approved by the end of 2021 .
With the expansion of production capacity, the approval of new indications and the development of overseas markets, Sintilimab's sales are expected to increase .
-
Eight departments issued the "Deepening Medical Service Price Reform Pilot Program"!
Time of Update: 2021-09-12
Answer: The "Pilot Plan" requires that people's health is the center, clinical value is the direction, and the law of medical development is the law, to establish and improve to adapt to economic and social development, to better play the role of the government, to fully participate in medical institutions, and to reflect the value of technical labor services.
-
1.5 billion oral hypoglycemic drugs welcome spoilers!
Time of Update: 2021-09-12
Medical News, September 1st, August 30th, the official website of the State Food and Drug Administration showed that Tonghua Dongbao Pharmaceutical was approved for imitation of Sitagliptin phosphate tablets for production in Category 4, and was deemed to have been reviewed .
-
With the reduction of wild resources, the contradiction between supply and demand of Acanthopanax senticosus has reached a critical point
Time of Update: 2021-09-12
After entering the 21st century, with the continuous deepening of scientific research, the use of Acanthopanax senticosus has been expanded to varying degrees, the market share has increased day by day, and the demand has also shown an upward trend year by year .
-
Jiangsu Province Solicits Opinions and Suggestions on Drug Safety Credit Management Measures
Time of Update: 2021-09-12
Medical Network News, August 31, August 25, Jiangsu Provincial Drug Administration issued an announcement on the "Jiangsu Province Drug Safety Credit Management Measures (Draft for Solicitation of Co
-
The status quo of the protection of special medicines for "Huiminbao", big data interpretation of 126 products!
Time of Update: 2021-09-12
At the same time, the compensation limit and payment ratio of the "Huiminbao" liability for special drugs are also not closely related to product prices .
-
The market for all fields of medicine has increased by 17.9%!
Time of Update: 2021-09-12
1 2012-2021 Q2 China's major cities drawing a sample hospital sales growth analysis we analyze each treatment according to ATC classification categories of the market, the first half of 2021, anti- cancer drugs and immune regulation inhibitors, and the whole digestive tract and systemic anti-infective drug metabolism The sales of drugs were 25.
-
Huge indemnities up to 160 million US dollars!
Time of Update: 2021-09-12
5 million in compensation Compared with the "huge compensation" of foreign companies such as Abbott and Medtronic, in contrast to domestic medical device procurement corruption cases, few domestic companies have paid the price for this, which is extremely ironic .
-
391 pharmaceutical companies posted transcripts for the first half of the year, 18 gross profit margins exceeded 90%
Time of Update: 2021-09-12
have also reached new highs; 13 companies such as Zhifei Bio, Mindray Medical, and Hengrui Pharmaceutical have net The profit exceeded 2 billion yuan; the gross profit margin of 18 companies including Ellis, Biotech, and Wuwu Biotech exceeded 90% .
-
Livzon innovative drugs sold over 5 billion!
Time of Update: 2021-09-12
According to the company's annual report data, after several years of polishing and accumulation after being approved for listing, the sales of ilaprazole enteric-coated tablets successfully exceeded 100 million yuan in 2014, and it has grown into a new growth point for the company's performance; in 2018, the injection formulation was officially launched.
-
The domestic recombinant insulin Qixiong contends for hegemony, the new force launches new challenges!
Time of Update: 2021-09-12
According to data from Mi Nei. com , in 2020, China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) will have a total sales of terminal insulin and similar products of nearly 27 billion yuan in 2020, a year-on-year increase.
-
5 billion new dosage forms of antihypertensive drugs, this pharmaceutical company will win
Time of Update: 2021-09-12
According to data from Mi Nei. com, in 2020, the total sales of valsartan in Chinese urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and the terminal valsartan in Chinese urban physical pharmacies will exceed 5 billion yuan.
-
50 billion!
Time of Update: 2021-09-12
According to incomplete statistics, 319 A-share and Hong Kong-listed pharmaceutical companies announced H1 R&D investment in 2021 (see the end of the article for details), with a total amount of nearly 50 billion yuan , Hengrui, Fosun, CSPC, Cinda and other blockbuster Class 1 new drugs are submitted for production .
-
Gansu Province: Several Measures to Promote the Inheritance, Innovation and Development of Traditional Chinese Medicine!
Time of Update: 2021-09-12
Provided by the national Chinese herbal medicine production enterprises, continuously strengthen the quality and safety supervision of the whole process from planting to use, improve the quality of Chinese herbal medicines, and promote the high-quality development of the Chinese medicine industry .
-
The list of key monitored drugs is adjusted once every three years and 30 varieties are included
Time of Update: 2021-09-12
All provincial health administrative departments shall, based on the 30 drug varieties submitted by the province, include them in the new version of the list of drug varieties, form a provincial-level key monitoring and rational use drug list, and report to the National Health Commission for the record in a timely manner .
